Oligodeoxynucleotides Lacking CpG Dinucleotides Mediate Toll-like Receptor 9 Dependent T Helper Type 2 Biased Immune Stimulation

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2004 Sep 24

PMID 15379982

Citations 39

Authors

Jorg Vollmer

Risini D Weeratna

Marion Jurk

Ulrike Samulowitz

Michael J McCluskie

Paul Payette

Heather L Davis

Christian Schetter

Arthur M Krieg

Affiliations

Soon will be listed here.

Abstract

Oligodeoxynucleotides (ODN) with unmethylated CpG dinucleotides mimic the immune stimulatory activity of bacterial DNA in vertebrates and are recognized by Toll-like receptor 9 (TLR9). It is also possible to detect immune activation with certain phosphorothioate sequences that lack CpG motifs. These ODN are less potent than CpG ODN and the mechanism by which they stimulate mammalian leucocytes is not understood. We here provide several lines of evidence demonstrating that the effects induced by non-CpG ODN are mediated by TLR9. First, non-CpG ODN could not stimulate cytokine secretion from the splenocytes of TLR9-deficient (TLR9(-/-)) mice. Second, immunization of TLR9(+/+) but not TLR9(-/-) mice with non-CpG ODN enhanced antigen-specific antibody responses, although these were T helper type 2 (Th2)-biased. Third, reactivity to non-CpG ODN could be reconstituted by transfection of human TLR9 into non-responsive cells. In addition, we define a new efficient immune stimulatory motif aside from the CpG dinucleotide that consists of a 5'-TC dinucleotide in a thymidine-rich background. Non-CpG ODN containing this motif induced activation of human B cells, but lacked stimulation of Th1-like cytokines and chemokines. Our study indicates that TLR9 can mediate either efficient Th1- or Th2-dominated effects depending on whether it is stimulated by CpG or certain non-CpG ODN.

Citing Articles

A review of the complex interplay between chemoresistance and lncRNAs in lung cancer.

Alnefaie G J Transl Med. 2024; 22(1):1109.

PMID: 39639388 PMC: 11619437. DOI: 10.1186/s12967-024-05877-2.

Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1.

El Boujnouni N, van der Bent M, Willemse M, t Hoen P, Brock R, Wansink D Mol Ther Nucleic Acids. 2023; 32:622-636.

PMID: 37200862 PMC: 10185704. DOI: 10.1016/j.omtn.2023.04.010.

Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes.

Ward G, Dalton 3rd R, Meyer B, McLemore A, Aldrich A, Lam N Int J Mol Sci. 2023; 24(4).

PMID: 36835307 PMC: 9966808. DOI: 10.3390/ijms24043896.

Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events.

Partridge W, Burel S, Ferng A, Xia S, Kwoh T, Henry S Clin Transl Sci. 2023; 16(4):575-580.

PMID: 36631935 PMC: 10087069. DOI: 10.1111/cts.13476.

Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells.

Kleemann J, Steinhorst K, Konig V, Zoller N, Cinatl Jr J, Ozistanbullu D Cancers (Basel). 2022; 14(19).

PMID: 36230620 PMC: 9562717. DOI: 10.3390/cancers14194698.

References

Chuang T, Lee J, Kline L, Mathison J, Ulevitch R . Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol. 2002; 71(3):538-44. View

Krieg A . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60. DOI: 10.1146/annurev.immunol.20.100301.064842. View

Vollmer J, Janosch A, Laucht M, Ballas Z, Schetter C, Krieg A . Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002; 12(3):165-75. DOI: 10.1089/108729002760220761. View

Sano K, Shirota H, Terui T, Hattori T, Tamura G . Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner. J Immunol. 2003; 170(5):2367-73. DOI: 10.4049/jimmunol.170.5.2367. View

Uhlmann E, Vollmer J . Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003; 6(2):204-17. View

Elias F, Flo J, Lopez R, Zorzopulos J, Montaner A, Rodriguez J . Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003; 171(7):3697-704. DOI: 10.4049/jimmunol.171.7.3697. View

Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T . The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003; 33(11):2987-97. DOI: 10.1002/eji.200324238. View

Latz E, Schoenemeyer A, Visintin A, Fitzgerald K, Monks B, Knetter C . TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004; 5(2):190-8. DOI: 10.1038/ni1028. View

Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M . Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004; 34(1):251-62. DOI: 10.1002/eji.200324032. View

10.

Diebold S, Kaisho T, Hemmi H, Akira S, Reis e Sousa C . Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004; 303(5663):1529-31. DOI: 10.1126/science.1093616. View

11.

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S . Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004; 303(5663):1526-9. DOI: 10.1126/science.1093620. View

12.

Zhang D, Zhang G, Hayden M, Greenblatt M, Bussey C, Flavell R . A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004; 303(5663):1522-6. DOI: 10.1126/science.1094351. View

13.

Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K . Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A. 2004; 101(10):3516-21. PMC: 373494. DOI: 10.1073/pnas.0400525101. View

14.

Cornelie S, Hoebeke J, Schacht A, Bertin B, Vicogne J, Capron M . Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J Biol Chem. 2004; 279(15):15124-9. DOI: 10.1074/jbc.M313406200. View

15.

Vollmer J, Jepsen J, Uhlmann E, Schetter C, Jurk M, Wader T . Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides. 2004; 14(1):23-31. DOI: 10.1089/154545704322988021. View

16.

Jurk M, Schulte B, Kritzler A, Noll B, Uhlmann E, Wader T . C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 2004; 209(1-2):141-54. DOI: 10.1016/j.imbio.2004.02.006. View

17.

Zhao Q, Matson S, Herrera C, Fisher E, Yu H, Krieg A . Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev. 1993; 3(1):53-66. DOI: 10.1089/ard.1993.3.53. View

18.

Stein C, Cheng Y . Antisense oligonucleotides as therapeutic agents--is the bullet really magical?. Science. 1993; 261(5124):1004-12. DOI: 10.1126/science.8351515. View

19.

Krieg A, Yi A, Matson S, Waldschmidt T, Bishop G, Teasdale R . CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995; 374(6522):546-9. DOI: 10.1038/374546a0. View

20.

Krieg A, Matson S, Fisher E . Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996; 6(2):133-9. DOI: 10.1089/oli.1.1996.6.133. View